Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 4, 2015 (11 years ago)

Bevacizumab 1.25 mg/0.05 mL in 3/10 mL 31 G 5/16" Syringe for…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Bevacizumab 1.25 mg/0.05 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal Rx -- Pine Pharmaceuticals, 100 Colvin Woods Pkwy Suite 300, Tonawanda, NY 14150.

Drug: Bevacizumab

Recalling firm
Pine Pharmaceuticals, LLC
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0581-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bevacizumab recalls

See all
Class III · Low risk

Bevacizumab 2.5 mg/0.1 mL

Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.

Terminated Labeling / mix-up Pine Pharmaceuticals, LLC NDC 69194-0458-1 D-0531-2023

Other recalls by Pine Pharmaceuticals, LLC

All 2015 recalls